ATTACHMENT 1

510(k) Summary Of Safety and Effectiveness Information Upon Which An Equivalence Determination Could be Made

Trade or Proprietary Name: GlyPro® Reagent
GlyPro® Calibrator
GlyPro® Low Control
GlyPro® High Control

Common or Usual Name: Assay, Glycosylated Hemoglobin

Classification Name: Glycosylated Hemoglobin Assay

Manufacturer: Genzyme Diagnostics
One Kendall Square
Cambridge, MA 02139-1562

Contact Person: Barbara Pizza, Manager, Regulatory Affairs, (617) 252-7953

The use of the Genzyme GlyPro® Reagent assay on the Dade Dimension® Analyzer Family is substantially equivalent to a currently marketed method for Genzyme GlyPro® Reagent assay on the Hitachi 911 Analyzer for the monitoring of Diabetes.

The Genzyme GlyPro® Assay System (consisting of Reagent, Calibrator, Low Control and High Control) is a quantitative method for the detection of glycated serum proteins in serum and plasma.

PERFORMANCE STUDIES

Comparative Performance Studies

A Comparative performance study was conducted using the Genzyme GlyPro® Reagent on the Hitachi 911 Analyzer (predicate method) and the Dade Dimension® AR and Dade Dimension® XL Analyzers.

The slope, intercept, correlation coefficient, and sample range for these comparisons are provided below.

DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration
2098 Gaither Road
Rockville MD 20850

MAR 21 2000

Ms. Barbara Pizza
Manager, Regulatory Affairs
Genzyme Corporation
One Kendall Square
Cambridge Massachusetts 02139-1562

Re: K000239
Trade Name: GlyPro® Reagent on the Dade Dimension® Analyzer Family
Regulatory Class: II
Product Code: LCP
Dated: January 27, 2000
Received: January 27, 2000

Dear Ms. Pizza:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".

Sincerely yours,

Steven Gutman

Steven I. Gutman, M.D., M.B.A.
Director
Division of Clinical Laboratory Devices
Office of Device Evaluation
Center for Devices and Radiological Health

Enclosure

3.0 INTENDED USE

510(k) Number (if known): K000239

Device Name: GlyPro® Reagent on the Dade Dimension® Analyzer Family

GlyPro Reagent

For the quantitative determination of glycated serum proteins.

Measurement of glycated serum protein is representative of mean blood glucose levels over the preceding 2-3 weeks.

For In Vitro Diagnostic Use.

GlyPro Calibrator

For calibration of the GlyPro® assay.

For In Vitro Diagnostic Use.

GlyPro Low and High Controls

To monitor the performance of the GlyPro® assay.

For In Vitro Diagnostic Use.

Peter E. Maher

(Division Sign-Off)
Division of Clinical Laboratory Devices
510(k) Number K000239

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED.)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use ✓ (Per 21 CFR 801.109) OR Over-The-Counter-Use ____ (Optional Format 1-2-96)